Premium
Intravesical Mitomycin C Therapy for Superficial Bladder Cancer. Report of a Multicentre Phase II Study
Author(s) -
MacFARLANE J. R.,
TOLLEY D. A.
Publication year - 1985
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1985.tb08980.x
Subject(s) - medicine , mitomycin c , urology , complete response , bladder cancer , transitional cell carcinoma , carcinoma , cancer , surgery , chemotherapy
Summary— Twenty‐five patients with early transitional cell carcinoma of the bladder (Tis Ta T1) received intravesical instillations of 40 mg mitomycin C in 40 ml water weekly for 7 weeks. The overall response rate was 70% (complete response 40%). In patients with Ta tumours the response rate was 86%. Minor toxic side effects occurred in four patients and only one patient was unable to complete the course of treatment because of side effects.